Drug repositioning for treatment of movement disorders: From serendipity to rational discovery strategies

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2337-2363

  Bolgár, Bence ^a   Arany, Ádám ^a,b   Temesi, Gergely ^a,b   Balogh, Balázs ^b   Antal, Péter ^a   Mátyus, Péter ^b,c  

^a BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c PÁZMÁNY PÉTER CATHOLIC UNIVERSITY   (Hungary)

Author keywords

Data fusion; In silico drug discovery; Movement disorders; Multi aspect drug repositioning; Multiple kernel learning; Parkinson's disease; Similarity search

Indexed keywords

ACETAZOLAMIDE; ALPRAZOLAM; AMFEBUTAMONE; BENZATROPINE; CARBAMAZEPINE; CLONIDINE; CREATINE; DEFERIPRONE; DEXTROMETHORPHAN; DIMEBON; DIPHENHYDRAMINE; GABAPENTIN; GUANFACINE; ISRADIPINE; MEMANTINE; METHYLPHENIDATE; MEXILETINE; MINOCYCLINE; OLANZAPINE; OXYBATE SODIUM; OXYCODONE; PRAMIPEXOLE; PREGABALIN; RASAGILINE; RILUZOLE; TOPIRAMATE; UBIDECARENONE; UNINDEXED DRUG; VIGABATRIN; ZONISAMIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIPOLAR DISORDER; COMPUTER MODEL; DRUG DESIGN; DRUG MEGADOSE; DRUG REPOSITIONING; DYSKINESIA; DYSTONIA; ESSENTIAL TREMOR; FOCAL EPILEPSY; GAIT DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; KERNEL METHOD; MIGRAINE; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; THALASSEMIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; MOVEMENT DISORDERS;

EID: 84887899544     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660164     Document Type: Article

References (193)

1. Walter, C.; Shah, A.; Nolte, M. Strategies to support drug discovery through integration of systems and data. Drug Discovery Today, 2007, 12(15-16), 634-639.
2. Berger, B.; Peng, J.; Singh, M. Computational solutions for omics data. Nature Reviews Genetics, 2013, 14(5), 333-346.
3. Scudellari, M. Data Deluge. Scientist, 2011, 25(10), 44-45.
4. Bell, G.; Hey, T.; Szalay, A. Beyond the Data Deluge. Science, 2009, 323(5919), 1297-1298.
5. Fernald, G.; Capriotti, E.; Daneshjou, R.; Karczewski, K.; Altman, R. Bioinformatics challenges for personalized medicine. Bioinformatics, 2011, 27(13), 1741-1748.
6. Li, Y. Y.; Jones, S. J. Drug repositioning for personalized medicine. Genome Med, 2012, 4(27).
7. Ma, Q.; Lu, A. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol. Rev, 2011, 63(2), 437-459.
8. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D.; Austin, C. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Science Translational Medicine, 2011, 3(80).
9. Yang, L.; Agarwal, P. Systematic Drug Repositioning Based on Clinical Side-Effects. Plos One, 2011, 6(12).
10. Jensen, P.; Jensen, L.; Brunak, S. Mining electronic health records: towards better research applications and clinical care. Nature Reviews Genetics, 2012, 13(6), 395-405.
11. Flower, D. R. Pharmacovigilance, Drug Repositioning, and Virtual Screening. J Pharmacovigilance, 2013, 1(1).
12. Eichler, H.; Oye, K.; Baird, L.; Abadie, E.; Brown, J.; Drum, C.; Ferguson, J.; Garner, S.; Honig, P.; Hukkelhoven, M.; Limn, J.; Lim, R.; Lumpkin, M.; Neil, G.; O'Rourke, B.; Pezalla, E.; Shoda, D.; Seyfert-Margolis, V.; Sigal, E.; Sobotka, J.; Tan, D.; Unger, T.; Hirsch, G. Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval. Clinical Pharmacology & Therapeutics, 2012, 91(3), 426-437.
13. Deloitte, T. R., 2012.
14. Ashburn, T.; Thor, K. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery, 2004, 3(8), 673-683.
15. Chiang, A.; Butte, A. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther, 2009, 86(5), 507-510.
16. Qu, X.; Gudivada, R.; Jegga, A.; Neumann, E.; Aronow, B. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinf, 2009, 10.
17. Dudley, J.; Sirota, M.; Shenoy, M.; Pai, R.; Roedder, S.; Chiang, A.; Morgan, A.; Sarwal, M.; Pasricha, P.; Butte, A. Computational repositioning of the anticonvulsant Topiramate for inflammatory bowel disease. Sci. Transl. Med, 2011, 3(96).
18. Dudley, J.; Deshpande, T.; Butte, A. Exploiting drug-disease relationships for computational drug repositioning. Briefings Bioinf, 2011, 12(4), 303-311.
19. Ekins, S.; Williams, A.; Krasowski, M.; Freundlich, J. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discovery Today, 2011, 16(7-8), 298-310.
20. Gottlieb, A.; Stein, G.; Ruppin, E.; Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol, 2011, 7.
21. Li, Y. Y.; An, J.; Jones, S. J. A computational approach to finding novel targets for existing drugs. PLoS Comput. Biol, 2011, 7(9), e1002139.
22. Sirota, M.; Dudley, J. T.; Kim, J.; Chiang, A. P.; Morgan, A. A.; Sweet-Cordero, A.; Sage, J.; Butte, A. J. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med, 2011, 3(96), 96ra77.
23. von Eichborn, J.; Murgueitio, M.; Dunkel, M.; Koerner, S.; Bourne, P.; Preissner, R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res, 2011, 39, D1060-D1066.
24. Arany, A.; Bolgar, B.; Balogh, B.; Antal, P.; Matyus, P. In Curr Med Chem: Netherlands, 2013; Vol. 20, pp 95-107.
25. Hurle, M.; Yang, L.; Xie, Q.; Rajpal, D.; Sanseau, P.; Agarwal, P. Computational Drug Repositioning: From Data to Therapeutics. Clinical Pharmacology & Therapeutics, 2013, 93(4), 335-341.
26. Andronis, C.; Sharma, A.; Virvilis, V.; Deftereos, S.; Persidis, A. Literature mining, ontologies and information visualization for drug repurposing. Briefings Bioinf, 2011, 12(4), 357-368.
27. Lussier, Y. A.; Chen, J. L. The emergence of genome-based drug repositioning. Sci. Transl. Med, 2011, 3(96), 96ps35.
28. Henrickson, J.; Johnson, M.; Maggiori, G. Concepts and applications of molecular similarity. Science, 1991, 252(5009), 1189-1189.
29. Kubinyi, H. Similarity and dissimilarity: A medicinal chemist's view. Perspectives in Drug Discovery and Design, 1998, 9-11, 225-252.
30. Willett, P.; Barnard, J.; Downs, G. Chemical similarity searching. J. Chem. Inf. Model, 1998, 38(6), 983-996.
31. Eckert, H.; Bajorath, J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discovery Today, 2007, 12(5-6), 225-233.
32. Kubinyi, H. Drug research: myths, hype and reality. Nature Reviews Drug Discovery, 2003, 2(8), 665-668.
33. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R.; Yang, L.; Jegga, A. Drug repositioning for orphan diseases. Briefings Bioinf, 2011, 12(4), 346-356.
34. Swamidass, S. Mining small-molecule screens to repurpose drugs. Briefings Bioinf, 2011, 12(4), 327-335.
35. Fahn, S. Classification of Movement Disorders. Movement Disorders, 2011, 26(6), 947-957.
36. Schapira, A.; Jenner, P. Etiology and Pathogenesis of Parkinson's Disease. Movement Disorders, 2011, 26(6), 1049-1055.
37. Paquette, M.; Martinez, A.; Macheda, T.; Meshul, C.; Johnson, S.; Berger, S.; Giuffrida, A. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. European Journal of Neuroscience, 2012, 36(9), 3224-3234.
38. Biton, V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol, 2007, 30(4), 230-240.
39. Leppik, I. E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure, 2004, 13 Suppl 1, S5-9; discussion S10.
40. Murata, M.; Horiuchi, E.; Kanazawa, I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res, 2001, 41(4), 397-399.
41. Yurekli, V. A.; Gurler, S.; Naziroglu, M.; Uguz, A. C.; Koyuncuoglu, H. R. Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell Mol Neurobiol, 2013, 33(2), 205-212.
42. Black, K. J.; Koller, J. M.; Campbell, M. C.; Gusnard, D. A.; Bandak, S. I. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci, 2010, 30(48), 16284-16292.
43. Matthews, R. T.; Ferrante, R. J.; Klivenyi, P.; Yang, L.; Klein, A. M.; Mueller, G.; Kaddurah-Daouk, R.; Beal, M. F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol, 1999, 157(1), 142-149.
44. Moreau, C.; Delval, A.; Tiffreau, V.; Defebvre, L.; Dujardin, K.; Duhamel, A.; Petyt, G.; Hossein-Foucher, C.; Blum, D.; Sablonniere, B.; Schraen, S.; Allorge, D.; Destee, A.; Bordet, R.; Devos, D. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry, 2013, 84(5), 552-555.
45. Verhagen Metman, L.; Blanchet, P. J.; van den Munckhof, P.; Del Dotto, P.; Natte, R.; Chase, T. N. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord, 1998, 13(3), 414-417.
46. Oakley, A. E.; Collingwood, J. F.; Dobson, J.; Love, G.; Perrott, H. R.; Edwardson, J. A.; Elstner, M.; Morris, C. M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology, 2007, 68(21), 1820-1825.
47. Dexter, D. T.; Statton, S. A.; Whitmore, C.; Freinbichler, W.; Weinberger, P.; Tipton, K. F.; Della Corte, L.; Ward, R. J.; Crichton, R. R. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm, 2011, 118(2), 223-231.
48. Silverdale, M. A.; Nicholson, S. L.; Crossman, A. R.; Brotchie, J. M. Topiramate reduces levodopa-induced dyskinesia in the MPTPlesioned marmoset model of Parkinson's disease. Mov Disord, 2005, 20(4), 403-409.
49. Quinn, L. P.; Crook, B.; Hows, M. E.; Vidgeon-Hart, M.; Chapman, H.; Upton, N.; Medhurst, A. D.; Virley, D. J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol, 2008, 154(1), 226-233.
50. Swanson, C. R.; Joers, V.; Bondarenko, V.; Brunner, K.; Simmons, H. A.; Ziegler, T. E.; Kemnitz, J. W.; Johnson, J. A.; Emborg, M. E. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation, 2011, 8, 91.
51. Aviles-Olmos, I.; Dickson, J.; Kefalopoulou, Z.; Djamshidian, A.; Ell, P.; Soderlund, T.; Whitton, P.; Wyse, R.; Isaacs, T.; Lees, A.; Limousin, P.; Foltynie, T. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest, 2013, 123(6), 2730-2736.
52. Dubois, B.; Tolosa, E.; Katzenschlager, R.; Emre, M.; Lees, A. J.; Schumann, G.; Pourcher, E.; Gray, J.; Thomas, G.; Swartz, J.; Hsu, T.; Moline, M. L. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord, 2012, 27(10), 1230-1238.
53. Ilijic, E.; Guzman, J. N.; Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis, 2011, 43(2), 364-371.
54. Moreau, C.; Delval, A.; Defebvre, L.; Dujardin, K.; Duhamel, A.; Petyt, G.; Vuillaume, I.; Corvol, J. C.; Brefel-Courbon, C.; Ory-Magne, F.; Guehl, D.; Eusebio, A.; Fraix, V.; Saulnier, P. J.; Lagha-Boukbiza, O.; Durif, F.; Faighel, M.; Giordana, C.; Drapier, S.; Maltete, D.; Tranchant, C.; Houeto, J. L.; Debu, B.; Sablonniere, B.; Azulay, J. P.; Tison, F.; Rascol, O.; Vidailhet, M.; Destee, A.; Bloem, B. R.; Bordet, R.; Devos, D. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol, 2012, 11(7), 589-596.
55. Levenga, J.; Hayashi, S.; de Vrij, F. M.; Koekkoek, S. K.; van der Linde, H. C.; Nieuwenhuizen, I.; Song, C.; Buijsen, R. A.; Pop, A. S.; Gomezmancilla, B.; Nelson, D. L.; Willemsen, R.; Gasparini, F.; Oostra, B. A. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis, 2011, 42(3), 311-317.
56. Berg, D.; Godau, J.; Trenkwalder, C.; Eggert, K.; Csoti, I.; Storch, A.; Huber, H.; Morelli-Canelo, M.; Stamelou, M.; Ries, V.; Wolz, M.; Schneider, C.; Di Paolo, T.; Gasparini, F.; Hariry, S.; Vandemeulebroecke, M.; Abi-Saab, W.; Cooke, K.; Johns, D.; Gomez-Mancilla, B. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord, 2011, 26(7), 1243-1250.
57. Rees, K.; Stowe, R.; Patel, S.; Ives, N.; Breen, K.; Clarke, C. E.; Ben-Shlomo, Y. Non-steroidal anti-inflammatory drugs as diseasemodifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev, 2011(11), Cd008454.
58. Gao, X.; Chen, H.; Schwarzschild, M. A.; Ascherio, A. Use of ibuprofen and risk of Parkinson disease. Neurology, 2011, 76(10), 863-869.
59. Hebron, M. L.; Lonskaya, I.; Moussa, C. E. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet, 2013.
60. Tonges, L.; Frank, T.; Tatenhorst, L.; Saal, K. A.; Koch, J. C.; Szego, E. M.; Bahr, M.; Weishaupt, J. H.; Lingor, P. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain, 2012, 135(Pt 11), 3355-3370.
61. Hornyak, M.; Scholz, H.; Kohnen, R.; Bengel, J.; Kassubek, J.; Trenkwalder, C. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev, 2013.
62. Benes, H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med, 2006, 7(1), 31-35.
63. Trenkwalder, C.; Benes, H.; Grote, L.; Happe, S.; Hogl, B.; Mathis, J.; Saletu-Zyhlarz, G. M.; Kohnen, R. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord, 2007, 22(5), 696-703.
64. Takeuchi, Y.; Takasu, K.; Ono, H.; Tanabe, M. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology, 2007, 53(7), 842-853.
65. Garcia-Borreguero, D.; Larrosa, O.; Williams, A. M.; Albares, J.; Pascual, M.; Palacios, J. C.; Fernandez, C. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology, 2010, 74(23), 1897-1904.
66. Walters, A. S.; Wagner, M. L.; Hening, W. A.; Grasing, K.; Mills, R.; Chokroverty, S.; Kavey, N. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep, 1993, 16(4), 327-332.
67. Babacan-Yildiz, G.; Gursoy, E.; Kolukisa, M.; Celebi, A. Restless legs syndrome responsive to rasagiline treatment: a case report. Clin Neuropharmacol, 2012, 35(2), 88-89.
68. Bayard, M.; Bailey, B.; Acharya, D.; Ambreen, F.; Duggal, S.; Kaur, T.; Rahman, Z. U.; Roller, K.; Tudiver, F. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med, 2011, 24(4), 422-428.
69. Perez Bravo, A. [Topiramate use as treatment in restless legs syndrome]. Actas Esp Psiquiatr, 2004, 32(3), 132-137.
70. Wagner, M. L.; Walters, A. S.; Coleman, R. G.; Hening, W. A.; Grasing, K.; Chokroverty, S. Randomized, double-blind, placebocontrolled study of clonidine in restless legs syndrome. Sleep, 1996, 19(1), 52-58.
71. Lauerma, H.; Markkula, J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry, 1999, 60(4), 241-244.
72. Grandjean, P. [Restless legs syndrome. Report of experience]. Schweiz Rundsch Med Prax, 1993, 82(43), 1195-1197.
73. Ondo, W. G. Methadone for refractory restless legs syndrome. Mov Disord, 2005, 20(3), 345-348.
74. Trenkwalder, C.; Hundemer, H. P.; Lledo, A.; Swieca, J.; Polo, O.; Wetter, T. C.; Ferini-Strambi, L.; de Groen, H.; Quail, D.; Brandenburg, U. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology, 2004, 62(8), 1391-1397.
75. Walters, A. S.; Hening, W. A.; Kavey, N.; Chokroverty, S.; Gidro-Frank, S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol, 1988, 24(3), 455-458.
76. Tribl, G. G.; Sycha, T.; Kotzailias, N.; Zeitlhofer, J.; Auff, E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry, 2005, 76(2), 181-185.
77. Ambrosio, A. F.; Soares-Da-Silva, P.; Carvalho, C. M.; Carvalho, A. P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res, 2002, 27(1-2), 121-130.
78. Telstad, W.; Sorensen, O.; Larsen, S.; Lillevold, P. E.; Stensrud, P.; Nyberg-Hansen, R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed), 1984, 288(6415), 444-446.
79. Eisensehr, I.; Ehrenberg, B. L.; Rogge Solti, S.; Noachtar, S. Treatment of idiopathic restless legs syndrome (RLS) with slowrelease valproic acid compared with slow-release levodopa/benserazid. J Neurol, 2004, 251(5), 579-583.
80. Montagna, P.; Sassoli de Bianchi, L.; Zucconi, M.; Cirignotta, F.; Lugaresi, E. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand, 1984, 69(6), 428-430.
81. Bezerra, M. L.; Martinez, J. V. Zolpidem in restless legs syndrome. Eur Neurol, 2002, 48(3), 180-181.
82. Boghen, D.; Lamothe, L.; Elie, R.; Godbout, R.; Montplaisir, J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci, 1986, 13(3), 245-247.
83. Evidente, V. G.; Adler, C. H.; Caviness, J. N.; Hentz, J. G.; Gwinn-Hardy, K. Amantadine is beneficial in restless legs syndrome. Mov Disord, 2000, 15(2), 324-327.
84. Louis, E.; Ferreira, J. How Common Is the Most Common Adult Movement Disorder? Update on the Worldwide Prevalence of Essential Tremor. Movement Disorders, 2010, 25(5), 534-541.
85. H, A.-N.; O, L.-B.; P, P. Update on genetics of essential tremor. ACTA NEUROLOGICA SCANDINAVICA 2013.
86. Abila, B.; Wilson, J. F.; Marshall, R. W.; Richens, A. The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by betaadrenoceptors located in a deep peripheral compartment. Br J Clin Pharmacol, 1985, 20(4), 369-376.
87. Jefferson, D.; Jenner, P.; Marsden, C. D. beta-Adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry, 1979, 42(10), 904-909.
88. Ondo, W. G.; Jankovic, J.; Connor, G. S.; Pahwa, R.; Elble, R.; Stacy, M. A.; Koller, W. C.; Schwarzman, L.; Wu, S. C.; Hulihan, J. F. Topiramate in essential tremor: a double-blind, placebocontrolled trial. Neurology, 2006, 66(5), 672-677.
89. Johannessen Landmark, C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs, 2008, 22(1), 27-47.
90. Herceg, M.; Nagy, F.; Pal, E.; Janszky, J.; Kesmarky, I.; Komoly, S.; Kovacs, N. Pramipexole may be an effective treatment option in essential tremor. Clin Neuropharmacol, 2012, 35(2), 73-76.
91. Handforth, A.; Martin, F. C.; Kang, G. A.; Vanek, Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord, 2009, 24(3), 437-440.
92. Zesiewicz, T. A.; Ward, C. L.; Hauser, R. A.; Salemi, J. L.; Siraj, S.; Wilson, M. C.; Sullivan, K. L. A pilot, double-blind, placebocontrolled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord, 2007, 22(11), 1660-1663.
93. Ferrara, J. M.; Kenney, C.; Davidson, A. L.; Shinawi, L.; Kissel, A. M.; Jankovic, J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci, 2009, 285(1-2), 195-197.
94. Elble, R. J.; Lyons, K. E.; Pahwa, R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol, 2007, 30(6), 350-356.
95. Frucht, S. J.; Houghton, W. C.; Bordelon, Y.; Greene, P. E.; Louis, E. D. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology, 2005, 65(12), 1967-1969.
96. Gunal, D. I.; Afsar, N.; Bekiroglu, N.; Aktan, S. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci, 2000, 21(5), 315-317.
97. Biary, N.; Koller, W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology, 1987, 37(3), 471-474.
98. Thompson, C.; Lang, A.; Parkes, J. D.; Marsden, C. D. A doubleblind trial of clonazepam in benign essential tremor. Clin Neuropharmacol, 1984, 7(1), 83-88.
99. Biary, N.; Bahou, Y.; Sofi, M. A.; Thomas, W.; al Deeb, S. M. The effect of nimodipine on essential tremor. Neurology, 1995, 45(8), 1523-1525.
100. Gironell, A.; Kulisevsky, J.; Barbanoj, M.; Lopez-Villegas, D.; Hernandez, G.; Pascual-Sedano, B. A randomized placebocontrolled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol, 1999, 56(4), 475-480.
101. Ondo, W.; Hunter, C.; Vuong, K. D.; Schwartz, K.; Jankovic, J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord, 2000, 15(4), 678-682.
102. Pahwa, R.; Lyons, K.; Hubble, J. P.; Busenbark, K.; Rienerth, J. D.; Pahwa, A.; Koller, W. C. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord, 1998, 13(3), 465-467.
103. Ceravolo, R.; Salvetti, S.; Piccini, P.; Lucetti, C.; Gambaccini, G.; Bonuccelli, U. Acute and chronic effects of clozapine in essential tremor. Mov Disord, 1999, 14(3), 468-472.
104. Serrano-Duenas, M. [Clonidine versus propranolol in the treatment of essential tremor. A double-blind trial with a one-year follow-up]. Neurologia, 2003, 18(5), 248-254.
105. Caccia, M. R.; Mangoni, A. Clonidine in essential tremor: preliminary observations from an open trial. J Neurol, 1985, 232(1), 55-57.
106. Koller, W.; Herbster, G.; Cone, S. Clonidine in the treatment of essential tremor. Mov Disord, 1986, 1(4), 235-237.
107. Jankovic, J.; Orman, J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology, 1988, 38(3), 391-394.
108. Chen, J. Y.; Wang, E. A.; Cepeda, C.; Levine, M. S. Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front Neurosci, 2013, 7, 114.
109. Deroover, J.; Baro, F.; Bourguignon, R. P.; Smets, P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin, 1984, 9(5), 329-338.
110. Bymaster, F. P.; Nelson, D. L.; DeLapp, N. W.; Falcone, J. F.; Eckols, K.; Truex, L. L.; Foreman, M. M.; Lucaites, V. L.; Calligaro, D. O. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res, 1999, 37(1), 107-122.
111. Yatham, L. N.; Goldstein, J. M.; Vieta, E.; Bowden, C. L.; Grunze, H.; Post, R. M.; Suppes, T.; Calabrese, J. R. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry, 2005, 66 Suppl 5, 40-48.
112. Grigorev, V. V.; Dranyi, O. A.; Bachurin, S. O. Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med, 2003, 136(5), 474-477.
113. Lermontova, N. N.; Redkozubov, A. E.; Shevtsova, E. F.; Serkova, T. P.; Kireeva, E. G.; Bachurin, S. O. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med, 2001, 132(5), 1079-1083.
114. Bachurin, S. O.; Shevtsova, E. P.; Kireeva, E. G.; Oxenkrug, G. F.; Sablin, S. O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci, 2003, 993, 334-344; discussion 345-339.
115. Network, H. I. o. t. H. S. G. a. E. H. s. D. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol, 2013, 70(1), 25-33.
116. Ryu, H.; Rosas, H. D.; Hersch, S. M.; Ferrante, R. J. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther, 2005, 108(2), 193-207.
117. Lin, Y. S.; Cheng, T. H.; Chang, C. P.; Chen, H. M.; Chern, Y. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease. Biochim Biophys Acta, 2013, 1832(6), 742-753.
118. Landwehrmeyer, G. B.; Dubois, B.; de Yebenes, J. G.; Kremer, B.; Gaus, W.; Kraus, P. H.; Przuntek, H.; Dib, M.; Doble, A.; Fischer, W.; Ludolph, A. C. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol, 2007, 62(3), 262-272.
119. Hickey, M. A.; Zhu, C.; Medvedeva, V.; Franich, N. R.; Levine, M. S.; Chesselet, M. F. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci, 2012, 49(2), 149-157.
120. Sancho, M.; Herrera, A. E.; Gortat, A.; Carbajo, R. J.; Pineda-Lucena, A.; Orzaez, M.; Perez-Paya, E. Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1. Hum Mol Genet, 2011, 20(18), 3545-3553.
121. A futility study of minocycline in Huntington's disease. Mov Disord, 2010, 25(13), 2219-2224.
122. Beister, A.; Kraus, P.; Kuhn, W.; Dose, M.; Weindl, A.; Gerlach, M. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl, 2004(68), 117-122.
123. O'Suilleabhain, P.; Dewey, R. B., Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol, 2003, 60(7), 996-998.
124. Verhagen Metman, L.; Morris, M. J.; Farmer, C.; Gillespie, M.; Mosby, K.; Wuu, J.; Chase, T. N. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology, 2002, 59(5), 694-699.
125. de Tommaso, M.; Difruscolo, O.; Sciruicchio, V.; Specchio, N.; Livrea, P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol, 2007, 30(1), 43-46.
126. Kumar, P.; Kumar, A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol, 2009, 615(1-3), 91-101.
127. Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord, 2009, 24(15), 2254-2259.
128. van Vugt, J. P.; Siesling, S.; Vergeer, M.; van der Velde, E. A.; Roos, R. A. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry, 1997, 63(1), 35-39.
129. Knight, T.; Steeves, T.; Day, L.; Lowerison, M.; Jette, N.; Pringsheim, T. Prevalence of Tic Disorders: A Systematic Review and Meta-Analysis. Pediatric Neurology, 2012, 47(2), 77-90.
130. O'Rourke, J. A.; Scharf, J. M.; Yu, D.; Pauls, D. L. The genetics of Tourette syndrome: a review. J Psychosom Res, 2009, 67(6), 533-545.
131. Wong, D. F.; Brasic, J. R.; Singer, H. S.; Schretlen, D. J.; Kuwabara, H.; Zhou, Y.; Nandi, A.; Maris, M. A.; Alexander, M.; Ye, W.; Rousset, O.; Kumar, A.; Szabo, Z.; Gjedde, A.; Grace, A. A. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology, 2008, 33(6), 1239-1251.
132. Scahill, L.; Leckman, J. F.; Schultz, R. T.; Katsovich, L.; Peterson, B. S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 2003, 60(7), 1130-1135.
133. Jankovic, J.; Jimenez-Shahed, J.; Brown, L. W. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry, 2010, 81(1), 70-73.
134. Guo, H.; Ou-Yang, Y. [Curative effect and possible mechanisms of topiramate in treatment of Tourette syndrome in rats]. Zhongguo Dang Dai Er Ke Za Zhi, 2008, 10(4), 509-512.
135. Johnson, B. A. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-ofconcept study. Alcohol Clin Exp Res, 2004, 28(8), 1137-1144.
136. Hedderick, E. F.; Morris, C. M.; Singer, H. S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol, 2009, 40(6), 420-425.
137. Du, Y. S.; Li, H. F.; Vance, A.; Zhong, Y. Q.; Jiao, F. Y.; Wang, H. M.; Wang, M. J.; Su, L. Y.; Yu, D. L.; Ma, S. W.; Wu, J. B. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry, 2008, 42(9), 807-813.
138. Singer, H. S.; Wendlandt, J.; Krieger, M.; Giuliano, J. Baclofen treatment in Tourette syndrome: a double-blind, placebocontrolled, crossover trial. Neurology, 2001, 56(5), 599-604.
139. Nicolson, R.; Craven-Thuss, B.; Smith, J.; McKinlay, B. D.; Castellanos, F. X. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette's disorder. J Am Acad Child Adolesc Psychiatry, 2005, 44(7), 640-646.
140. Acosta, M. T.; Castellanos, F. X. Use of the "inverse neuroleptic" metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol, 2004, 14(1), 123-128.
141. Toren, P.; Weizman, A.; Ratner, S.; Cohen, D.; Laor, N. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 2005, 66(4), 499-503.
142. Egel, R. T.; Hoganson, G. E.; Katerji, M. A.; Borenstein, M. J. Zonisamide ameliorates symptoms of secondary paroxysmal dystonia. Pediatr Neurol, 2010, 43(3), 205-208.
143. Lucetti, C.; Nuti, A.; Gambaccini, G.; Bernardini, S.; Brotini, S.; Manca, M. L.; Bonuccelli, U. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol, 2000, 23(4), 186-189.
144. Hering, S.; Wenning, G. K.; Seppi, K.; Poewe, W.; Mueller, J. An open trial of levetiracetam for segmental and generalized dystonia. Mov Disord, 2007, 22(11), 1649-1651.
145. Sullivan, K. L.; Hauser, R. A.; Louis, E. D.; Chari, G.; Zesiewicz, T. A. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord, 2005, 11(7), 469-471.
146. Hsieh, P. C.; Chen, S. M.; Guo, Y. H.; Kuan, T. S.; Yen, W. J.; Chang, W. C.; Lin, Y. C. Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature. Neuropsychiatr Dis Treat, 2013, 9, 445-448.
147. Richter, A.; Hamann, M. The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster. Eur J Pharmacol, 2004, 502(1-2), 105-108.
148. van't Groenewout, J. L.; Stone, M. R.; Vo, V. N.; Truong, D. D.; Matsumoto, R. R. Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine. Exp Neurol, 1995, 134(2), 253-260.
149. Granana, N.; Ferrea, M.; Scorticati, M. C.; Diaz, S.; Arrebola, M.; Torres, L.; Micheli, F. Beneficial effects of diphenhydramine in dystonia. Medicina (B Aires), 1999, 59(1), 38-42.
150. Burke, R. E.; Fahn, S.; Marsden, C. D. Torsion dystonia: a doubleblind, prospective trial of high-dosage trihexyphenidyl. Neurology, 1986, 36(2), 160-164.
151. Epstein, N. L. Benztropine for acute muscle spasm in the emergency department. Cmaj, 2001, 164(2), 203-204.
152. Goff, D. C.; Arana, G. W.; Greenblatt, D. J.; Dupont, R.; Ornsteen, M.; Harmatz, J. S.; Shader, R. I. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol, 1991, 11(2), 106-112.
153. Reeves, R. R.; Liberto, V. Treatment of essential blepharospasm with quetiapine. Mov Disord, 2003, 18(9), 1072-1073.
154. Karp, B. I.; Goldstein, S. R.; Chen, R.; Samii, A.; Bara-Jimenez, W.; Hallett, M. An open trial of clozapine for dystonia. Mov Disord, 1999, 14(4), 652-657.
155. Trugman, J. M.; Leadbetter, R.; Zalis, M. E.; Burgdorf, R. O.; Wooten, G. F. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord, 1994, 9(4), 441-446.
156. Jankovic, J.; Beach, J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997, 48(2), 358-362.
157. Chen, J. J.; Ondo, W. G.; Dashtipour, K.; Swope, D. M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther, 2012, 34(7), 1487-1504.
158. Thaker, G. K.; Nguyen, J. A.; Strauss, M. E.; Jacobson, R.; Kaup, B. A.; Tamminga, C. A. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry, 1990, 147(4), 445-451.
159. Miyazaki, Y.; Sato, K.; Koizumi, H.; Sako, W.; Asanuma, K.; Kaji, R. [New medications for dystonia]. Rinsho Shinkeigaku, 2012, 52(11), 1074-1076.
160. Ha, S.; Seo, Y.; Kwon, M.; Chang, B.; Han, C.; Yoon, J. IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics, 2008, 24(11), 1413-1415.
161. Li, Y.; An, J.; Jones, S. A computational approach to finding novel targets for existing drugs. PLoS Comput. Biol, 2011, 7(9).
162. Sirota, M.; Dudley, J.; Kim, J.; Chiang, A.; Morgan, A.; Sweet-Cordero, A.; Sage, J.; Butte, A. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med, 2011, 3(96).
163. Vapnik, V. An overview of statistical learning theory. Ieee Trans. Neural Netw, 1999, 10(5), 988-999.
164. Ginn, C.; Turner, D.; Willett, P.; Ferguson, A.; Heritage, T. Similarity searching in files of three-dimensional chemical structures: Evaluation of the EVA descriptor and combination of rankings using data fusion. J. Chem. Inf. Model, 1997, 37(1), 23-37.
165. Ginn, C.; Willett, P.; Bradshaw, J. Combination of molecular similarity measures using data fusion. Perspect. Drug Discovery Des, 2000, 20(1), 1-16.
166. Whittle, M.; Gillet, V.; Willett, P.; Loesel, J. Analysis of data fusion methods in virtual screening: Similarity and group fusion. J. Chem. Inf. Model, 2006, 46(6), 2206-2219.
167. Whittle, M.; Gillet, V.; Willett, P. Analysis of data fusion methods in virtual screening: Theoretical model. J. Chem. Inf. Model, 2006, 46(6), 2193-2205.
168. Willett, P. Enhancing the effectiveness of ligand-based virtual screening using data fusion. QSAR Comb. Sci, 2006, 25(12), 1143-1152.
169. Swann, S.; Brown, S.; Muchmore, S.; Patel, H.; Merta, P.; Locklear, J.; Hajduk, P. A inified, probabilistic framework for structure-and ligand-based virtual screening. J. Med. Chem, 2011, 54(5), 1223-1232.
170. Chen, B.; Harrison, R.; Papadatos, G.; Willett, P.; Wood, D.; Lewell, X.; Greenidge, P.; Stiefl, N. Evaluation of machinelearning methods for ligand-based virtual screening. J. Comput.-Aided Mol. Des, 2007, 21(1-3), 53-62.
171. Keiser, M.; Roth, B.; Armbruster, B.; Ernsberger, P.; Irwin, J.; Shoichet, B. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol, 2007, 25(2), 197-206.
172. Keiser, M.; Setola, V.; Irwin, J.; Laggner, C.; Abbas, A.; Hufeisen, S.; Jensen, N.; Kuijer, M.; Matos, R.; Tran, T.; Whaley, R.; Glennon, R.; Hert, J.; Thomas, K.; Edwards, D.; Shoichet, B.; Roth, B. Predicting new molecular targets for known drugs. Nature, 2009, 462(7270), 175-U148.
173. Bubendorf, L. High-throughput microarray technologies: From genomics to clinics. European Urology, 2001, 40(2), 231-238.
174. Moreau, Y.; Tranchevent, L. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nature Reviews Genetics, 2012, 13(8), 523-536.
175. Freudenberg, J.; Propping, P. A similarity-based method for genome-wide prediction of disease-relevant human genes. Bioinformatics, 2002, 18, S110-S115.
176. Kohler, S.; Bauer, S.; Horn, D.; Robinson, P. Walking the interactome for prioritization of candidate disease genes. American Journal of Human Genetics, 2008, 82(4), 949-958.
177. Dunkel, P.; Chai, C.; Sperlagh, B.; Huleatt, P.; Matyus, P. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2012, 21(9), 1267-1308.
178. Foltynie, T.; Kahan, J. Parkinson's disease: an update on pathogenesis and treatment. Journal of Neurology, 2013, 260(5), 1433-1440.
179. Hussl, A.; Seppi, K.; Poewe, W. Nonmotor symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2013, 13(6), 581-583.
180. Ahmed, I.; Bose, S.; Pavese, N.; Ramlackhansingh, A.; Turkheimer, F.; Hotton, G.; Hammers, A.; Brooks, D. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain, 2011, 134, 979-986.
181. Wolpert, D. The lack of A priori distinctions between learning algorithms. Neural Computation, 1996, 8(7), 1341-1390.
182. Campillos, M.; Kuhn, M.; Gavin, A.; Jensen, L.; Bork, P. Drug target identification using side-effect similarity. Science, 2008, 321(5886), 263-266.
183. Lamb, J.; Crawford, E.; Peck, D.; Modell, J.; Blat, I.; Wrobel, M.; Lerner, J.; Brunet, J.; Subramanian, A.; Ross, K.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S.; Haggarty, S.; Clemons, P.; Wei, R.; Carr, S.; Lander, E.; Golub, T. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313(5795), 1929-1935.
184. Svensson, F.; Karlen, A.; Skold, C. Virtual Screening Data Fusion Using Both Structure-and Ligand-Based Methods. J Chem Inf Model, 2012, 52(1), 225-232.
185. Perot, S.; Sperandio, O.; Miteva, M.; Camproux, A.; Villoutreix, B. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discovery Today, 2010, 15(15-16), 656-667.
186. Hofmann, T.; Scholkopf, B.; Smola, A. Kernel methods in machine learning. Annals of Statistics, 2008, 36(3), 1171-1220.
187. Shi, Z.; Ma, X. H.; Qin, C.; Jia, J.; Jiang, Y. Y.; Tan, C. Y.; Chen, Y. Z. Combinatorial support vector machines approach for virtual screening of selective multi-target serotonin reuptake inhibitors from large compound libraries. J. Mol. Graphics Modell, 2012, 32(0), 49-66.
188. Wang, Y.; Zhang, C.; Deng, N.; Wang, Y. Kernel-based data fusion improves the drug-protein interaction prediction. Comput. Biol. Chem, 2011, 35(6), 353-362.
189. Agarwal, S.; Dugar, D.; Sengupta, S. Ranking Chemical Structures for Drug Discovery: A New Machine Learning Approach. J. Chem. Inf. Model, 2010, 50(5), 716-731.
190. Fechner, N.; Jahn, A.; Hinselmann, G.; Zell, A. Estimation of the applicability domain of kernel-based machine learning models for virtual screening. J. Cheminf, 2010, 2(1), 2.
191. Warmuth, M.; Liao, J.; Ratsch, G.; Mathieson, M.; Putta, S.; Lemmen, C. Active learning with support vector machines in the drug discovery process. J. Chem. Inf. Model, 2003, 43(2), 667-673.
192. Burbidge, R.; Trotter, M.; Buxton, B.; Holden, S. Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput. Chem. (Oxford, U. K.), 2001, 26(1), 5-14.
193. Navlakha, S.; Kingsford, C. The power of protein interaction networks for associating genes with diseases. Bioinformatics, 2010, 26(8), 1057-1063.